Research company Hamlet Biopharma reported zero revenue again and a reduced operating loss in the fourth quarter of the broken financial year 2025/2026.EBITDA was -13.4 million kronor (-15.2).Operating profit, EBIT, amounted to -15.9 million kronor (-17.7).Net profit was -15.9 million kronor (-17.5).Earnings per share amounted to -0.0852 kronor (-0.0985).Cash and cash equivalents amounted to 5.1 million kronor (10.8) at the end of the period.”We have maintained strong momentum in both therapeutic areas, with important progress. These successes reflect our teams’ commitment and provide a solid foundation for continued progress in the coming period,” comments CEO Jakob Testad.Key figures, SEK millionQ4 2025/2026Q4 2024/2025Year-on-year changeRevenue0.00.0-EBITDA-13.4-15.2-EBIT-15.9-17.7-Net profit-15.9-17.5-Earnings per share, kronor-0.0852-0.0985-Cash and cash equivalents5.110.8-52.7%